Adamis Pharmaceuticals Corp., of San Diego, said the FDA approved its epinephrine (adrenaline) injection (0.3 mg pre-filled single dose syringe) for the emergency treatment of type I allergic reactions, including anaphylaxis, and also approved the trade name Symjepi. The product includes two single-dose syringes. The company did not disclose pricing but said it expected a “lower cost, small size and user-friendly design” in comparison to the Epipen (epinephrine injection) auto-injector marketed by Mylan NV, of Canonsburg, Pa. Adamis said it was exploring commercialization options and is in discussions with potential partners to optimize patient access while beginning to build inventory levels to prepare for an anticipated launch in the second half of the year. Following disclosure of FDA approval, shares of Adamis (NASDAQ:ADMP) spiked to a 52-week high, gaining $2, or 53.3 percent, to close at $5.75. In June 2016, Adamis received a complete response letter from the FDA, which questioned the volume of dosage the syringe delivered, including what was claimed in the label and required by the agency.